Fredun Pharmaceuticals Limited's shares rose 3% on Tuesday, May 26, following the company's announcement of a 2:1 bonus issue alongside strong Q4 financial results. According to the company's press release, the board approved the audited Q4 and FY26 financial results at its meeting held on May 25, 2026, and recommended the issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of ₹10 each for every 1 existing equity share of ₹10 each. The bonus issue is subject to shareholder approval and will be distributed to eligible shareholders and warrant holders as on the record date.
The company reported robust financial results for the March 2026 quarter, with consolidated net profit surging 79.67% year-on-year to ₹10.78 crore, driven by healthy demand across various segments. Consolidated revenue for the quarter increased 27.18% YoY to ₹210.41 crore, while operating profit margin (OPM) expanded to 13.73% from 10.43% in the previous year. For the full financial year FY26, consolidated net profit rose 65.25% YoY to ₹32.62 crore, while consolidated sales increased 40.21% to ₹633.33 crore compared to ₹451.71 crore in FY25. The company highlighted that margins improved across the board due to operating leverage benefits and disciplined cost management, with profitability accelerating faster than revenue growth, indicating improving business quality.
Fredun Pharmaceuticals operates across multiple business verticals including branded generic exports across 52 countries, domestic Fredun Gx formulations, nutraceuticals, cosmeceuticals under Bird N Beauty, and its integrated pet healthcare platform comprising Freossi, Wagr and One Pet Stop. Managing Director Fredun Medhora noted that the balanced mix across segments is helping the company scale sustainably and reduce dependence on any single segment. The company has started investing in the next phase of growth with the launch of the premium hormone therapy range and the DAULCÉL platform, marking its entry into more specialized, wellness and preventive healthcare segments. Medhora emphasized that the expansion of the Palghar facility and upgrade in credit rating will provide the capacity and financial strength to support future growth.
The stock rose as much as 2.7% to its day's high of ₹2,450 per share on BSE, with strong performance across multiple timeframes. According to reports, the stock has added 13.5% in 1 month, 46% in 3 months, and 28% in 6 months, while delivering multibagger returns of 225% in the last 1 year and 471% over the past 5 years. The company also declared a dividend of ₹0.70 per share for shareholders alongside the bonus issue announcement. The company will continue to focus on building presence across segments while gradually increasing the share of differentiated and higher value products.
